OSE Pharma (France) Performance
| OSE Stock | EUR 8.89 0.21 2.42% |
On a scale of 0 to 100, OSE Pharma holds a performance score of 7. The company holds a Beta of 0.0243, which implies not very significant fluctuations relative to the market. As returns on the market increase, OSE Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding OSE Pharma is expected to be smaller as well. Please check OSE Pharma's value at risk, kurtosis, and the relationship between the sortino ratio and semi variance , to make a quick decision on whether OSE Pharma's historical price patterns will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in OSE Pharma SA are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak technical and fundamental indicators, OSE Pharma sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 29.4 M | |
| Total Cashflows From Investing Activities | -827 K |
OSE |
OSE Pharma Relative Risk vs. Return Landscape
If you would invest 739.00 in OSE Pharma SA on August 27, 2024 and sell it today you would earn a total of 150.00 from holding OSE Pharma SA or generate 20.3% return on investment over 90 days. OSE Pharma SA is generating 0.3727% of daily returns assuming 4.1931% volatility of returns over the 90 days investment horizon. Simply put, 37% of all stocks have less volatile historical return distribution than OSE Pharma, and 93% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
OSE Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for OSE Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as OSE Pharma SA, and traders can use it to determine the average amount a OSE Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0889
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | OSE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.19 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.37 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average OSE Pharma is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of OSE Pharma by adding it to a well-diversified portfolio.
OSE Pharma Fundamentals Growth
OSE Stock prices reflect investors' perceptions of the future prospects and financial health of OSE Pharma, and OSE Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on OSE Stock performance.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0528 | |||
| Profit Margin | (0.22) % | |||
| Operating Margin | (0.25) % | |||
| Current Valuation | 128.18 M | |||
| Shares Outstanding | 18.44 M | |||
| Price To Earning | 10.60 X | |||
| Price To Book | 2.64 X | |||
| Price To Sales | 3.69 X | |||
| Revenue | 26.31 M | |||
| EBITDA | (13.72 M) | |||
| Cash And Equivalents | 33.58 M | |||
| Cash Per Share | 0.84 X | |||
| Total Debt | 34.77 M | |||
| Debt To Equity | 7.20 % | |||
| Book Value Per Share | 2.53 X | |||
| Cash Flow From Operations | (9.92 M) | |||
| Earnings Per Share | (0.41) X | |||
| Total Asset | 101.88 M | |||
| Retained Earnings | 25 M | |||
| Current Asset | 30 M | |||
| Current Liabilities | 8 M | |||
About OSE Pharma Performance
By analyzing OSE Pharma's fundamental ratios, stakeholders can gain valuable insights into OSE Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if OSE Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if OSE Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
OSE Immunotherapeutics SA, a biotechnology company, focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. OSE Immunotherapeutics SA is headquartered in Nantes, France. OSE IMMUNO operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 34 people.Things to note about OSE Pharma SA performance evaluation
Checking the ongoing alerts about OSE Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for OSE Pharma SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| OSE Pharma SA had very high historical volatility over the last 90 days | |
| The company reported the revenue of 26.31 M. Net Loss for the year was (16.85 M) with profit before overhead, payroll, taxes, and interest of 26.31 M. | |
| OSE Pharma SA has accumulated about 33.58 M in cash with (9.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.84. | |
| Roughly 39.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing OSE Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether OSE Pharma's stock is overvalued or undervalued compared to its peers.
- Examining OSE Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating OSE Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of OSE Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of OSE Pharma's stock. These opinions can provide insight into OSE Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for OSE Stock analysis
When running OSE Pharma's price analysis, check to measure OSE Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OSE Pharma is operating at the current time. Most of OSE Pharma's value examination focuses on studying past and present price action to predict the probability of OSE Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OSE Pharma's price. Additionally, you may evaluate how the addition of OSE Pharma to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |